Nicolás Flores

A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C

Antonio Ojea, José Luís Nogueira, Eduardo Solsona et al. · European Urology · 2007 · 211 citations

Medicine, Oncology, Urology +10

HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL

J A Martínez-Piñeiro, Luis Martínez‐Piñeiro, Eduardo Solsona et al. · The Journal of Urology · 2005 · 198 citations

Medicine, Oncology, Urology +10

Original Articles: Bladder Cancer: Neoadjuvant Cisplatin Chemotherapy Before Radical Cystectomy in Invasive Transitional Cell Carcinoma of the Bladder: A Prospective Randomized Phase III Study

J A Martínez-Piñeiro, M. González Martín, Fernando Arocena et al. · The Journal of Urology · 1995 · 162 citations

Medicine, Oncology, Surgery +11

CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells

David Krige, Lindsey Needham, Lindsay J. Bawden et al. · Cancer Research · 2008 · 117 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia

Bob Löwenberg, Gareth J. Morgan, Gert J. Ossenkoppele et al. · Journal of Clinical Oncology · 2010 · 74 citations

Medicine, Pharmacology, Pharmacotherapy +15